James S Liljestrand, MD | |
Masspro, 245 Winter Street, Waltham, MA 02451 | |
(781) 419-2785 | |
Not Available |
Full Name | James S Liljestrand |
---|---|
Gender | Male |
Speciality | Preventive Medicine - Public Health & General Preventive Medicine |
Location | Masspro, Waltham, Massachusetts |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1942349733 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2083P0901X | Preventive Medicine - Public Health & General Preventive Medicine | 34762 (Massachusetts) | Primary |
Mailing Address | Practice Location Address |
---|---|
James S Liljestrand, MD 396 Lexington Rd, Concord, MA 01742-3713 Ph: (781) 419-2785 | James S Liljestrand, MD Masspro, 245 Winter Street, Waltham, MA 02451 Ph: (781) 419-2785 |
News Archive
Antimicrobial packaging is being developed to extend the shelf life and safety of foods and beverages. However, there is concern about the transfer of potentially harmful materials, such as silver nanoparticles, from these types of containers to consumables.
CRF Health, a leading provider of ePRO solutions for the Life Sciences industry, today announced it has relocated from Lansdale, PA to newly opened offices in Plymouth Meeting, PA. The two new office locations include North American corporate headquarters and new logistics and warehousing facilities. The facility expansion supports CRF Health's continued growth in the global ePRO market.
The McDonald Criteria for the Diagnosis of Multiple Sclerosis have just been revised by a 30-member international panel of MS experts co-chaired by Jeffrey Cohen, MD (Cleveland Clinic) and Alan Thompson, MD (University College London).
Vaccination efforts have rolled out in most countries starting in the last quarter of 2020 with more than 2.37 billion vaccines administered worldwide so far. However, reports of cardiac inflammation (myocarditis and pericarditis) occurring after the mRNA COVID-19 vaccination (Pfizer-BioNTech and Moderna) have increased in the United States since April 2021.
Administration of a bolus dose of the anticoagulant drug abciximab into the coronary artery involved in causing a certain type of heart attack among patients who were undergoing a percutaneous coronary intervention and also receiving another anticoagulant resulted in reduction in the size of damage to the heart muscle at 30 days, while a procedure that involved use of a catheter to remove the blood clot blocking that coronary artery did not produce these results, according to a study appearing in JAMA.
› Verified 2 days ago
Dr. Sandra Diane Stratford, MD, MSC Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 1601 Trapelo Rd, Suite 176, Waltham, MA 02451 Phone: 781-290-2210 Fax: 781-290-2215 |